The Use of Recombinant Cholera Toxin-B for the Treatment of Inflammatory Bowel Disease

The present invention provides methods of treating inflammatory bowel disease in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B (CT-B). In particular, the present invention provides methods of decreasing the activity of interferon-gamma in a subject, decreasing the activity of IL-12 in a subject, and treating or preventing a Th1 T-cell mediated autoimmune disorder.

Inventors:

Warren Strober (NIAID)  ➽ more inventions...

Monica Boirivant

Brian Kelsall (NIAID)  ➽ more inventions...


Intellectual Property:
US Pat: 7,041,296 issued 2006-05-09
US Application No. 60/165,111 filed on 1999-11-12
PCT Application No. PCT/US00/30837 filed on 2000-11-09

Licensing Contact:
Charles Rainwater,
Email: crainwater@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: E-263-1999-0
Updated: Jul 16, 2010